Other viral diseases

This category is identified in the payload as “Other viral diseases” with ICD-10 code B33, but the sources do not define it as one specific pathogen or one uniform clinical entity ^[1][2][3]. The cited literature uses the phrase in broader contexts of viral illness, antiviral therapy, diagnostic methods, and post-transplant viral disease, indicating that it functions as a residual or umbrella grouping rather than a discrete infection ^[4][5][6]. A more specific etiologic characterization is not supported by the supplied snippets ^[1][2][3].

The source set does not provide a single clinical syndrome, symptom pattern, or complication profile for this category as a whole ^[1][2][3]. One review notes that virus infection after hematopoietic stem cell transplantation remains an appreciable cause of morbidity and mortality, and that some viral infections in this setting may be difficult to prevent or treat because of toxicity or resistance ^[5]. Another source describes COVID-19 as an emerging disease that created a global pandemic and challenged health systems, while remdesivir data are discussed in relation to reduced time to recovery in hospitalized patients requiring supplemental oxygen ^[6][4]. Because these observations refer to specific viral illnesses rather than the category itself, broader clinical features are not yet available from the provided evidence ^[4][5][6].

The epidemiologic information in the sources is fragmented and disease-specific rather than category-wide ^[1][2][3]. The most explicit population context is viral disease after hematopoietic stem cell transplantation, where infection remains an appreciable cause of morbidity and mortality, and some infections are increasingly detected after alternative donor transplants ^[5]. Another source states that COVID-19 spread worldwide since the end of 2019 and caused a global pandemic ^[6]. The remaining sources reference RNA-virus targets such as ebolavirus, MERS-CoV, SARS-CoV, and SARS-CoV-2 in the context of antiviral research, but they do not establish epidemiology for “other viral diseases” as a whole ^[4].

No single transmission route is described for this umbrella category in the supplied material ^[1][2][3]. The sources only indicate that the cited viral agents include respiratory pathogens such as MERS-CoV, SARS-CoV, and SARS-CoV-2, and also ebolavirus, but they do not state transmission mechanisms in these snippets ^[4]. Because the category spans multiple viral illnesses, source-backed transmission detail is not yet available at the category level ^[4][5][6].

Source-backed higher-risk context is most clearly described for people after hematopoietic stem cell transplantation, where viral infection remains an appreciable cause of morbidity and mortality and some infections are increasingly detected after alternative donor transplants ^[5]. The evidence also identifies hospitalized patients requiring supplemental oxygen in COVID-19 treatment studies, but that is a disease-specific treatment population rather than a general risk group for the category ^[4]. No broader risk-group profile for “other viral diseases” is established in the provided snippets ^[1][2][3].

The supplied evidence does not support a unified prevention strategy for “other viral diseases” as a whole ^[1][2][3]. One review notes that pharmacotherapy and antibody therapy may help prevent or treat viral disease in post-transplant settings, but it also emphasizes expense, toxicity, and resistance as limitations ^[5]. A separate source discusses laboratory diagnosis methods for COVID-19, reflecting the need for sensitive detection in public health response, but it does not provide preventive guidance for this category ^[6]. Broadly applicable exposure-control or vaccination detail is not yet available from the provided snippets ^[4][5][6].

For surveillance purposes, this code should be read as a nonspecific residual category rather than as a single pathogen-defined event ^[1][2][3]. The available sources point to several distinct monitoring contexts, including global COVID-19 detection efforts, post-transplant viral infections, and research on antivirals spanning multiple RNA viruses ^[4][5][6]. Case interpretation therefore requires attention to the specific virus, clinical context, and source document, because category-level attribution is not supported by the supplied evidence ^[4][5][6].

1. 1 Other Viral Diseases. Health Maintenance Of Cultured Fishes. 2018. doi: 10.1201/9781351073141-12. DOI: https://doi.org/10.1201/9781351073141-12
2. 2 Other Viral Diseases. Uveitis. 2010. doi: 10.1016/b978-1-4377-0667-3.00018-7. DOI: https://doi.org/10.1016/b978-1-4377-0667-3.00018-7
3. 3 Other Viral Diseases. Whitcup and Nussenblatt's Uveitis. 2020. doi: 10.1016/b978-0-323-48014-7.00014-2. DOI: https://doi.org/10.1016/b978-0-323-48014-7.00014-2
4. 4 Malin JJ et al. Remdesivir against COVID-19 and Other Viral Diseases. Clin Microbiol Rev. 2020 Dec 16. PMID: 33055231. doi: 10.1128/CMR.00162-20. PubMed: https://pubmed.ncbi.nlm.nih.gov/33055231/
5. 5 Barrett AJ et al. Virus-Specific T Cells: Broadening Applicability. Biol Blood Marrow Transplant. 2018 Jan. PMID: 29032062. doi: 10.1016/j.bbmt.2017.10.004. PubMed: https://pubmed.ncbi.nlm.nih.gov/29032062/
6. 6 Pohanka M et al. COVID-19 molecular level laboratory diagnoses. Bratisl Lek Listy. 2021. PMID: 33393315. doi: 10.4149/BLL_2021_025. PubMed: https://pubmed.ncbi.nlm.nih.gov/33393315/

ICD-10

B33

ICD-11

Total cases

0

Peak month

2012-09

Coverage

1 reporting countries · 2012-09-14 → 2026-06-20